Health news
The Food and Drug Administration (FDA) has approved Medtronic’s IntellisTM rechargeable neurostimulator and VantaTM recharge-free neurostimulator for the treatment of pain associated with diabetic peripheral neuropathy (DPN). These implantable spinal cord stimulation (SCS) devices were…
Non-invasive skin autofluorescence (SAF) is a reliable measurement of advanced glycation end products (AGE) which contribute to diabetic end-organ damage. High SAF levels demonstrate significant associations with diabetic retinopathy, diabetic peripheral neuropathy, diabetic nephropathy, diabetic…
Citing racism as the “root cause” of health disparities in the US and worldwide, the Endocrine Society issued a policy statement addressing the sources and impact of racism in endocrine health disparities. The statement was…
Novo Nordisk announced the availability of Rybelsus® (semaglutide) tablets 3mg, 7mg, or 14mg in 30-count recyclable bottles. Rybelsus is a glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve…
The Mediterranean Diet was picked as the best diet overall for 2022, according to new rankings released by US News and World Report. An expert panel assessed 40 diets to come up with the final…
Among patients with painful diabetic neuropathy (PDN), high frequency spinal cord stimulation (SCS) had a higher long term pain response compared with pharmacotherapy. These findings were published in Diabetes Care. Patients (N=216) with PDN for…
The Food and Drug Administration (FDA) has approved Rezvoglar (insulin glargine-aglr), the second biosimilar product to Lantus (insulin glargline). Rezvoglar is a long-acting human insulin analogue indicated to improve glycemic control in adults and pediatric…
Patients with glycated hemoglobin levels (HbA1c) just below the diagnostic threshold for diabetes have the highest risk of major adverse cardiovascular events (MACE) and all-cause mortality, according to a study in Diabetes Care. Using registry…
Empagliflozin (EMPA) has demonstrated a greater benefit for those with vs without cardiovascular disease (CVD) in older patients with Type 2 diabetes, according to study results presented at AHA 2021, held from November 13 to…
Low rates of treatment deintensification following a severe hypoglycemic episode suggest discordance between guidelines and practice, according to the findings of a cohort study recently published in JAMA Network Open. Although evidence-based guidelines recommend deintensification…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021